US › Healthcare

Dare Bioscience Inc (DARE)

US · Healthcare · Biotechnology

$0.75+3.07%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$187,546

Net profit

$-3.0M

EPS

$-0.20

EPS estimate

$-0.33

Net margin

-1,590.4%

EPS came in at -0.20 against a street estimate of -0.33 — a beat of 39.4%.

Key statistics

Market cap

$13.9M

Forward P/E

1.3

P/B

29.40

Book value

$-0.04

EPS (TTM)

$-0.66

52-week high

$3.78

52-week low

$0.69

50-day MA

$1.25

200-day MA

$1.80

Beta

1.01

Analyst view

Analysts rate Dare Bioscience Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $8.33.

Shareholding

Insiders

12.08%

Institutions

13.37%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.39%
Geode Capital Management, LLC	0.92%
U.S. Bancorp	0.47%
Vanguard Fiduciary Trust Co	0.34%
UBS Group AG	0.22%
State Street Corp	0.12%
XTX Topco Ltd	0.12%
Susquehanna International Group, LLP	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dare Bioscience Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.